ENTRY       D03257                      Drug
NAME        Trastuzumab (USAN/INN);
            Trastuzumab (genetical recombination) (JAN);
            Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN);
            Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN);
            Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN);
            Trastuzumab-pkrb;
            Trastuzumab-anns;
            Trastuzumab-dkst;
            Trastuzumab-dttb;
            Trastuzumab-qyyp;
            Trastuzumab-anns;
            Herceptin (TN);
            Herzuma (TN);
            Kanjinti (TN);
            Ogivri (TN);
            Ontruzant (TN)
PRODUCT     HERCEPTIN (Genentech)
            HERZUMA (Cephalon)
            KANJINTI (Amgen)
            OGIVRI (Mylan Institutional LLC)
            ONTRUZANT (Organon LLC)
            TRAZIMERA (Pfizer Laboratories Div Pfizer)
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY
            ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPG
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
            RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H147-H203, H264-H324, H370-H428, H229-H'229, H232-H'232, L23-L88, L134-L194, H223-L214)
  TYPE      Peptide
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03158  HER2 inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FD01
            Product: D03257<JP/US>
            Product (mixture): D11560<US> D11934<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  DISEASE   Breast cancer (HER2 overexpressing) [DS:H00031]
            Gastric cancer (HER2 overexpressing) [DS:H00018]
  TYPE      Monoclonal antibody
TARGET      ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  PATHWAY   hsa04012(2064)  ErbB signaling pathway
            hsa05200(2064)  Pathways in cancer
            hsa05224(2064)  Breast cancer
            hsa05226(2064)  Gastric cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
                 L01FD01 Trastuzumab
                  D03257  Trastuzumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Trastuzumab
                D03257  Trastuzumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D03257  Trastuzumab (USAN/INN); Trastuzumab (genetical recombination) (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03158  HER2 inhibitor
                 D03257  Trastuzumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03158  HER2 inhibitor
               D03257  Trastuzumab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
                 D03257  Trastuzumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03257
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03257
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D03257
DBLINKS     CAS: 180288-69-1
            PubChem: 17397410
            NIKKAJI: J2.044.149F
///
